The buy-now-pay-later provider has expanded its integration with Apple Pay to include physical retail locations across the ...

The rally in uranium-related stocks comes as the U.S. government looks to strengthen its domestic uranium reserves, which are critical for nuclear power generation and national security purposes.

Investing.com -- Israeli Prime Minister Benjamin Netanyahu informed U.S. President Donald Trump about Israel’s plan to attack Hamas leaders in Qatar before the strike took place last week, according ...

Investing.com -- Fiverr International is restructuring its operations, cutting approximately 250 jobs across departments as part of a transformation to become an "AI-first company," according to a ...

Rambus Inc. (NASDAQ:RMBS) stock soared 16% Monday after Baird analyst Tristan Gerra raised his price target on the semiconductor company to $120 from $90 while maintaining an Outperform rating. The ...

Bullard led the St. Louis Fed from 2008 to 2023 before transitioning to his academic role at Purdue. The Trump administration is actively interviewing candidates to replace current Fed Chair Jerome ...

California Resources Corporation said Monday it will acquire Berry Corporation in an all-stock transaction valuing the oil producer at about $717 million, including net debt. Shares of Berry surged 14 ...

The offering, priced at $13.53 per share, consists of 46,112,899 shares being sold by affiliates of Pearl Energy Investments and Riverstone Investment Group LLC. Permian Resources will not receive any ...

Investing.com - Futures linked to Canada’s main stock exchange pointed higher on Monday, as investors looked ahead to key ...

Investing.com -- DallasNews Corporation (NASDAQ:DALN) stock surged 10.5% in premarket trading Monday after the company announced Hearst has increased its acquisition offer to $16.50 per share in cash, ...

Investing.com -- CoreWeave stock surged 9% Monday morning following the announcement of a significant cloud computing agreement with NVIDIA Corporation (NASDAQ:NVDA).

Investing.com -- aTyr Pharma (NASDAQ:ATYR) stock fell 80% after the company announced that its Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis failed to meet its primary endpoint.